Favorable outcomes of SGLT2 inhibitor use in pacemaker recipients: a population-based study
Main finding · All-cause deathResult — go to the resultHazard ratio 0.62 95% CI 0.50–0.78Authors' conclusion
SGLT2i therapy was associated with reduced risk of all-cause mortality and HF-related hospitalizations following pacemaker implantation. Future randomized studies are needed to confirm this association.
Study context
- Population
- Patients with conventional pacemakers implanted for atrioventricular block, 2016–2024; excluded sinus node dysfunction or iatrogenic pacing indications, single-chamber devices and eGFR <20 mL/min/1.73m2eligible
- Participants
- 11,518 patients
- Exposure
- Baseline SGLT2i therapy vs no SGLT2i
- SGLT2in = 1,226
- Non-SGLT2in = 1,226reference
- Outcome
- All-cause mortality and heart failure (HF) hospitalization; events within 3 months post-implantation omitted
- Follow-up
- 3 years
Methodological detailspopulation-based, propensity score matched
- Population-based
- Propensity score matched
Main finding
All-cause death
Hazard ratio
0.62
95% CI 0.50–0.78
P < 0.001
Events by group
SGLT2ivs Non-SGLT2i
HR 0.62 (95% CI 0.50–0.78); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | SGLT2i | Non-SGLT2i | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| HF hospitalization · 3 years | 10.7% | 22.8% | 0.50 (0.41–0.62) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Subgroup analyses
- Consistent effects across strata
Original publication
Favorable outcomes of SGLT2 inhibitor use in pacemaker recipients: a population-based study. Cardiovasc Diabetol. Published 14 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →